EX-99.1 2 orgo-ex99_1.htm EX-99.1 EX-99.1

Exhibit 99.1

img36819578_0.jpg

 

FOR IMMEDIATE RELEASE

 

Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results

 

CANTON, Mass., (May 8, 2025) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2025.

 

First Quarter 2025 Financial Results Summary:

 

•
Net revenue of $86.7 million for the first quarter of 2025, a decrease of $23.3 million compared to net revenue of $110.0 million for the first quarter of 2024. Net revenue for the first quarter of 2025 consists of:
o
Net revenue from Advanced Wound Care products of $79.9 million, a decrease of 23% from the first quarter of 2024.
o
Net revenue from Surgical & Sports Medicine products of $6.8 million, an increase of 11% from the first quarter of 2024.
•
Net loss of $18.8 million for the first quarter of 2025, compared to a net loss of $2.1 million for the first quarter of 2024, an increase in net loss of $16.7 million.
•
Adjusted net loss of $13.4 million for the first quarter of 2025, compared to an adjusted net loss of $1.4 million for the first quarter of 2024, an increase in adjusted net loss of $12.0 million.
•
Adjusted EBITDA loss of $12.5 million for the first quarter of 2025, compared to Adjusted EBITDA income of $2.6 million for the first quarter of 2024, a decrease of $15.1 million.

 

“I’m proud of the team’s continued dedication to our customers and their patients in this challenging market. We managed the anticipated disruption well and I’m confident in our ability to execute on our commercial strategy for the remainder of the year,” said Gary S. Gillheeney, Sr., President, Chief Executive Officer and Chair of the Board for Organogenesis. “With our strong brand equity, diverse portfolio and deep customer relationships, we remain well-positioned to navigate the evolving reimbursement landscape.”

 

Mr. Gillheeney, Sr. continued: “We continue to progress the ReNu development plan with all patients expected to complete the second phase 3 study by the end of the second quarter and remain on track to submit the BLA by the end of 2025.”

 

 

 

 

 

 

 

 

 

 

 

 

 

First Quarter 2025 Financial Results:



 

 

Three Months Ended March 31,

 

 

Change

 

 

 

2025

 

 

2024

 

 

$

 

 

%

 

 

 

(in thousands, except for percentages)

 

Advanced Wound Care

 

$

79,927

 

 

$

103,864

 

 

$

(23,937

)

 

 

(23

%)

Surgical & Sports Medicine

 

 

6,766

 

 

 

6,112

 

 

 

654

 

 

 

11

%

Net revenue

 

$

86,693

 

 

$

109,976

 

 

$

(23,283

)

 

 

(21

%)

 

Net revenue for the first quarter of 2025 was $86.7 million, compared to $110.0 million for the first quarter of 2024, a decrease of $23.3 million, or 21%. The decrease in net revenue was driven by a decrease of $23.9 million, or 23%, in net revenue for Advanced Wound Care products partially offset by an increase of $0.7 million, or 11%, in net revenue for Surgical & Sports Medicine products.

 

Gross profit for the first quarter of 2025 was $63.0 million, or 73% of net revenue, compared to $81.3 million, or 74% of net revenue for the first quarter of 2024, a decrease of $18.3 million, or 23%.

 

Operating expenses for the first quarter of 2025 were $89.7 million compared to $85.1 million for the first quarter of 2024, an increase of $4.6 million, or 5%. R&D expense was $10.6 million for the first quarter of 2025, compared to $12.8 million for the first quarter of 2024, a decrease of $2.2 million, or 17%. Selling, general and administrative expenses were $72.5 million for the first quarter of 2025, compared to $72.3 million for the first quarter of 2024, an increase of $0.2 million, or less than 1%. For the three months ended March 31, 2025, the Company recorded write down expenses of $6.6 million.

 

Operating loss for the first quarter of 2025 was $26.7 million, compared to an operating loss of $3.9 million for the first quarter of 2024, an increase in operating loss of $22.9 million.

 

Total other (income) expense, net, for the first quarter of 2025 was $(1.0) million income, compared to $0.5 million expense for the first quarter of 2024, a change of $1.5 million.

 

Net loss for the first quarter of 2025 was $18.8 million, or $(0.17) per share, compared to net loss of $2.1 million, or $(0.02) per share, for the first quarter of 2024, an increase in net loss of $16.7 million, or $(0.15) per share.

 

Adjusted net loss was $13.4 million for the first quarter of 2025, compared to adjusted net loss of $1.4 million for the first quarter of 2024, an increase in adjusted net loss of $12.0 million.

 

Adjusted EBITDA loss was $(12.5) million for the first quarter of 2025, compared to Adjusted EBITDA income of $2.6 million for the first quarter of 2024, a change of $15.1 million.

 

Non-GAAP operating loss was $19.3 million for the first quarter of 2025, compared to non-GAAP operating loss of $3.0 million for the first quarter of 2024, a change of $16.4 million.

 

As of March 31, 2025, the Company had $110.5 million in cash, cash equivalents and restricted cash and no outstanding debt obligations, compared to $136.2 million in cash, cash equivalents and restricted cash and no outstanding debt obligations as of December 31, 2024.

 

 

 

 

Fiscal Year 2025 Guidance:

 

For the year ending December 31, 2025, the Company is reaffirming its prior revenue guidance and updating its profitability guidance and expects:

•
Net revenue between $480.0 million and $535.0 million, representing a year-over-year change in the range of a roughly flat to an increase of 11%, as compared to net revenue of $482.0 million for the year ended December 31, 2024.
o
The 2025 net revenue guidance range assumes:
▪
Net revenue from Advanced Wound Care products between $450.0 million and $500.0 million, a decrease of 1% to an increase of 10% year-over-year as compared to net revenue of $453.6 million for the year ended December 31, 2024.
▪
Net revenue from Surgical & Sports Medicine products between $30.0 million and $35.0 million, an increase of 6% to 23% year-over-year as compared to net revenue of $28.4 million for the year ended December 31, 2024.
•
Net income between $4.7 million and $34.0 million and adjusted net income between $15.3 million and $44.6 million.
•
EBITDA between $20.0 million and $59.6 million and Adjusted EBITDA between $43.6 million and $83.2 million.

 

First Quarter Earnings Conference Call:

 

Management will host a conference call at 5:00 p.m. Eastern Time on May 8th to discuss the results of the quarter, and provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here or access the teleconference here. The live webcast can also be accessed via the company's website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ORGANOGENESIS HOLDINGS INC.

UNAUDITED CONSOLIDATED BALANCE SHEETS

(amounts in thousands, except share and per share data)

 

 

 

March 31,

 

 

December 31,

 

 

 

2025

 

 

2024

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

109,965

 

 

$

135,571

 

Restricted cash

 

 

569

 

 

 

580

 

Accounts receivable, net

 

 

103,320

 

 

 

109,861

 

Inventories, net

 

 

29,338

 

 

 

26,219

 

Asset held for sale (Note 6)

 

 

7,033

 

 

 

—

 

Prepaid expenses and other current assets

 

 

17,935

 

 

 

13,710

 

Total current assets

 

 

268,160

 

 

 

285,941

 

Property and equipment, net

 

 

75,518

 

 

 

89,128

 

Intangible assets, net

 

 

11,626

 

 

 

12,468

 

Goodwill

 

 

28,772

 

 

 

28,772

 

Operating lease right-of-use assets, net

 

 

36,756

 

 

 

37,110

 

Deferred tax asset, net

 

 

40,728

 

 

 

39,462

 

Other assets

 

 

5,834

 

 

 

5,005

 

Total assets

 

$

467,394

 

 

$

497,886

 

Liabilities, Redeemable Convertible Preferred Stock, and Stockholders’ Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Current portion of finance lease obligations

 

$

1,193

 

 

$

1,170

 

Current portion of operating lease obligations - related party

 

 

3,712

 

 

 

3,671

 

Current portion of operating lease obligations

 

 

4,353

 

 

 

4,272

 

Accounts payable

 

 

24,660

 

 

 

28,911

 

Accrued expenses and other current liabilities

 

 

31,135

 

 

 

39,453

 

Total current liabilities

 

 

65,053

 

 

 

77,477

 

Finance lease obligations, net of current portion

 

 

411

 

 

 

718

 

Operating lease obligations, net of current portion - related party

 

 

7,339

 

 

 

8,283

 

Operating lease obligations, net of current portion

 

 

25,625

 

 

 

25,198

 

Other liabilities

 

 

897

 

 

 

894

 

Total liabilities

 

 

99,325

 

 

 

112,570

 

Commitments and contingencies (Note 15)

 

 

 

 

 

 

 

 

 

 

 

 

Series A redeemable convertible preferred stock, $0.0001 par value; 130,000 shares authorized, issued and outstanding at March 31, 2025 and December 31, 2024; liquidation preference of $134,014 and $131,387 at March 31, 2025 and December 31, 2024, respectively.

 

 

125,167

 

 

 

122,419

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Preferred stock, $0.0001 par value; 870,000 shares authorized at March 31, 2025 and December 31, 2024, respectively; none issued or outstanding

 

 

—

 

 

 

—

 

Common stock, $0.0001 par value; 400,000,000 shares authorized; 127,582,084 and 126,458,784 shares issued; 126,853,536 and 125,730,236 shares outstanding at March 31, 2025 and December 31, 2024, respectively.

 

 

13

 

 

 

13

 

Additional paid-in capital

 

 

301,842

 

 

 

302,994

 

Accumulated deficit

 

 

(58,953

)

 

 

(40,110

)

Total stockholders’ equity

 

 

242,902

 

 

 

262,897

 

Total liabilities, redeemable convertible preferred stock, and stockholders' equity

 

$

467,394

 

 

$

497,886

 

 

 

 

ORGANOGENESIS HOLDINGS INC. UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(amounts in thousands, except share and per share data)

 

 

 

 

Three Months Ended
March 31,

 

 

 

2025

 

 

2024

 

Net revenue

 

$

86,693

 

 

$

109,976

 

Cost of goods sold

 

 

23,723

 

 

 

28,696

 

Gross profit

 

 

62,970

 

 

 

81,280

 

Operating expenses:

 

 

 

 

 

 

Selling, general and administrative

 

 

72,509

 

 

 

72,322

 

Research and development

 

 

10,640

 

 

 

12,810

 

Write-down to fair value for asset held for sale

 

 

6,567

 

 

 

—

 

Total operating expenses

 

 

89,716

 

 

 

85,132

 

Loss from operations

 

 

(26,746

)

 

 

(3,852

)

Other expense, net:

 

 

 

 

 

 

Interest income (expense), net

 

 

961

 

 

 

(514

)

Other income, net

 

 

2

 

 

 

23

 

Total other income (expense), net

 

 

963

 

 

 

(491

)

Net loss before income taxes

 

 

(25,783

)

 

 

(4,343

)

Income tax benefit

 

 

6,940

 

 

 

2,243

 

Net loss and comprehensive loss

 

 

(18,843

)

 

 

(2,100

)

Accretion of redeemable convertible preferred stock to redemption value

 

 

(121

)

 

 

—

 

Cumulative dividend on redeemable convertible preferred stock

 

 

(2,627

)

 

 

—

 

Net loss attributable to common stockholders

 

$

(21,591

)

 

$

(2,100

)

 

 

 

 

 

 

 

Net loss, per share:

 

 

 

 

 

 

Basic and diluted

 

$

(0.17

)

 

$

(0.02

)

Weighted-average common shares outstanding

 

 

 

 

 

 

Basic and diluted

 

 

126,295,642

 

 

 

131,861,772

 

 

 

 

ORGANOGENESIS HOLDINGS INC. UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS

(amounts in thousands, except share and per share data)

 

 

 

 

Three Months Ended
March 31,

 

 

 

2025

 

 

2024

 

Cash flows from operating activities:

 

 

 

 

 

 

Net loss

 

$

(18,843

)

 

$

(2,100

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

Depreciation and amortization

 

 

3,444

 

 

 

3,072

 

Amortization of intangible assets

 

 

842

 

 

 

901

 

Reduction in the carrying value of right-of-use assets

 

 

1,997

 

 

 

2,203

 

Non-cash interest expense

 

 

69

 

 

 

105

 

Deferred interest expense

 

 

—

 

 

 

122

 

Deferred tax benefit

 

 

(1,266

)

 

 

—

 

Provision recorded for credit losses

 

 

873

 

 

 

968

 

Loss on disposal of property and equipment

 

 

19

 

 

 

347

 

Adjustment for excess and obsolete inventories

 

 

3,709

 

 

 

2,515

 

Stock-based compensation

 

 

3,367

 

 

 

2,407

 

Write-down to fair value for asset held for sale

 

 

6,567

 

 

 

—

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable

 

 

5,668

 

 

 

(15,117

)

Inventories

 

 

(8,732

)

 

 

(4,670

)

Prepaid expenses and other current assets and other assets

 

 

(5,123

)

 

 

(4,315

)

Operating leases

 

 

(2,037

)

 

 

(2,199

)

Accounts payable

 

 

(2,496

)

 

 

(4,391

)

Accrued expenses and other liabilities

 

 

(7,993

)

 

 

9,990

 

Net cash used in operating activities

 

 

(19,935

)

 

 

(10,162

)

Cash flows from investing activities:

 

 

 

 

 

 

Purchases of property and equipment

 

 

(3,626

)

 

 

(2,222

)

Net cash used in investing activities

 

 

(3,626

)

 

 

(2,222

)

Cash flows from financing activities:

 

 

 

 

 

 

Payments of term loan under the 2021 Credit Agreement

 

 

—

 

 

 

(1,406

)

Payments of withholding taxes in connection with RSUs vesting

 

 

(1,796

)

 

 

(1,120

)

Proceeds from the exercise of stock options

 

 

25

 

 

 

180

 

Principal repayments of finance lease obligations

 

 

(285

)

 

 

(262

)

Net cash used in financing activities

 

 

(2,056

)

 

 

(2,608

)

Change in cash, cash equivalents and restricted cash

 

 

(25,617

)

 

 

(14,992

)

Cash, cash equivalents, and restricted cash, beginning of period

 

 

136,151

 

 

 

104,338

 

Cash, cash equivalents, and restricted cash, end of period

 

$

110,534

 

 

$

89,346

 

Supplemental disclosure of cash flow information:

 

 

 

 

 

 

Cash paid for interest

 

$

—

 

 

$

1,375

 

Cash paid for income taxes

 

$

150

 

 

$

35

 

Supplemental disclosure of non-cash investing and financing activities:

 

 

 

 

 

 

Accretion to redemption value and cumulative dividends on redeemable convertible preferred stock

 

$

2,748

 

 

$

—

 

Purchases of property and equipment included in accounts payable and accrued expenses

 

$

172

 

 

$

786

 

Right-of-use assets obtained through operating lease obligations

 

$

1,642

 

 

$

701

 

 

 

 

 

Non-GAAP Financial Measures

Our management uses financial measures that are not in accordance with generally accepted accounting principles in the United States, or GAAP, in addition to financial measures in accordance with GAAP to evaluate our operating results. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with GAAP. Our management uses Adjusted EBITDA and adjusted net income (loss) to evaluate our operating performance and trends and make planning decisions. Our management believes Adjusted EBITDA, adjusted net income (loss) and non-GAAP operating income (loss) help identify underlying trends in our business that could otherwise be masked by the effect of the items that we exclude. Accordingly, we believe that Adjusted EBITDA, adjusted net income (loss) and non-GAAP operating income (loss) provide useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and prospects, and allowing for greater transparency with respect to key financial metrics used by our management in its financial and operational decision-making.

Adjusted EBITDA

Adjusted EBITDA consists of GAAP net loss excluding: (i) interest (income) expense, net, (ii) income tax (benefit), (iii) depreciation and amortization, (iv) amortization of intangible assets, (v) stock-based compensation expense, and (vi) additional infrequently occurring adjustments described in more detail below.

The following table presents a reconciliation of GAAP net loss to non-GAAP EBITDA and non-GAAP Adjusted EBITDA, for the periods presented:

 

 

 

Three Months Ended March 31,

 

 

 

2025

 

 

2024

 

 

 

(Unaudited, in thousands)

 

Net loss

 

$

(18,843

)

 

$

(2,100

)

Interest (income) expense, net

 

 

(961

)

 

 

514

 

Income tax benefit

 

 

(6,940

)

 

 

(2,243

)

Depreciation and amortization

 

 

3,444

 

 

 

3,072

 

Amortization of intangible assets

 

 

842

 

 

 

901

 

EBITDA

 

 

(22,458

)

 

 

144

 

Stock-based compensation expense

 

 

3,367

 

 

 

2,407

 

Write-down to fair value for asset held for sale1

 

 

6,567

 

 

—

 

Adjusted EBITDA

 

$

(12,524

)

 

$

2,551

 
(1)
Amount reflects the fair value adjustment of a purchased building classified as held for sale.

 

 

Adjusted Net Loss

Adjusted net loss is defined as GAAP net loss plus (i) amortization of intangible assets and (ii) additional infrequently occurring adjustments described in more detail below, less the estimated tax on these adjustments.

The following table presents a reconciliation of GAAP net loss to non-GAAP adjusted net loss, for the periods presented:

 

 

 

Three Months Ended March 31,

 

 

 

2025

 

 

2024

 

 

 

(Unaudited, in thousands)

 

Net loss

 

$

(18,843

)

 

$

(2,100

)

Amortization of intangible assets

 

 

842

 

 

 

901

 

Write-down to fair value for asset held for sale1

 

 

6,567

 

 

—

 

Tax on above

 

 

(2,000

)

 

 

(241

)

Adjusted net loss

 

$

(13,434

)

 

$

(1,440

)
(1)
Amount reflects the fair value adjustment of a purchased building classified as held for sale.

 

Non-GAAP Operating Loss

Non-GAAP operating loss is defined as GAAP loss from operations plus (i) amortization of intangible assets and (ii) fair value adjustments related to a purchased building classified as held for sale.

The following table presents a reconciliation of GAAP net loss from operations to non-GAAP operating loss, for the periods presented:

 

 

Three Months Ended March 31,

 

 

 

2025

 

 

2024

 

 

 

(Unaudited, in thousands)

 

Loss from operations

 

$

(26,746

)

 

$

(3,852

)

Amortization of intangible assets

 

 

842

 

 

 

901

 

Write-down to fair value for asset held for sale1

 

 

6,567

 

 

—

 

Non-GAAP operating loss

 

$

(19,337

)

 

$

(2,951

)
(1)
Amount reflects the fair value adjustment of a purchased building classified as held for sale.

 

Projected EBITDA and Adjusted EBITDA

The following table presents a reconciliation of projected GAAP net income to projected non-GAAP EBITDA and projected non-GAAP Adjusted EBITDA included in our guidance for the year ending December 31, 2025:

 

 

 

Year Ended December 31,

 

 

 

2025L

 

 

2025H

 

Net income

 

$

4,700

 

 

$

34,000

 

Interest income

 

 

(4,000

)

 

 

(4,000

)

Income tax expense

 

 

1,400

 

 

 

11,700

 

Depreciation and amortization

 

 

14,600

 

 

 

14,600

 

Amortization of intangible assets

 

 

3,300

 

 

 

3,300

 

EBITDA

 

$

20,000

 

 

$

59,600

 

Stock-based compensation expense

 

 

12,400

 

 

 

12,400

 

Write-down to fair value for asset held for sale1

 

 

6,600

 

 

 

6,600

 

FDA fee

 

 

4,600

 

 

 

4,600

 

Adjusted EBITDA

 

$

43,600

 

 

$

83,200

 
(1)
Amount reflects the fair value adjustment of a purchased building classified as held for sale.

 

 

 

Projected Adjusted Net Income

The following table presents a reconciliation of projected GAAP net income to projected non-GAAP adjusted net income included in our guidance for the year ending December 31, 2025:

 

 

 

Year Ending December 31,

 

 

 

2025L

 

 

2025H

 

Net income

 

$

4,700

 

 

$

34,000

 

Amortization of intangible assets

 

 

3,300

 

 

 

3,300

 

Write-down to fair value for asset held for sale1

 

 

6,600

 

 

 

6,600

 

FDA fee

 

 

4,600

 

 

 

4,600

 

Tax on above

 

 

(3,900

)

 

 

(3,900

)

Adjusted net income

 

$

15,300

 

 

$

44,600

 
(1)
Amount reflects the fair value adjustment of a purchased building classified as held for sale.

 

 

Forward-Looking Statements

 

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include statements relating to the Company’s expected revenue, net income, adjusted net income, EBITDA, and Adjusted EBITDA for fiscal 2025 and the breakdown of expected revenue in both its Advanced Wound Care and Surgical & Sports Medicine categories. Forward-looking statements with respect to the operations of the Company, strategies, prospects, and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact and uncertainty of any changes to the coverage and reimbursement levels for the Company’s products (including as a result of the proposed LCDs that could take effect as soon as January 1, 2026); (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company’s products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete; (4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company’s ability to raise funds to expand its business; (6) the Company has incurred losses in the current period and prior periods and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company’s ability to maintain production or obtain supply of its products in sufficient quantities to meet demand; (10) any resurgence of the COVID-19 pandemic and its impact, if any, on the Company’s fiscal condition and results of operations; (11) the impact of the suspension of commercialization of: (a) ReNu and NuCel in connection with the expiration of the FDA’s enforcement grace period for HCT/Ps on May 31, 2021 and (b) Dermagraft in the second quarter of 2022 pending transition of manufacturing to a new manufacturing facility or a third-party manufacturer; (12) whether the Company is able to obtain regulatory approval for and successfully commercialize ReNu; and (13) other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including Item 1A (Risk Factors) of the Company’s Form 10-K for the year ended December 31, 2024 and its subsequently filed periodic reports. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

 

 

 

 

 

 

 

 

 

About Organogenesis Holdings Inc.

Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.

 

Investor Inquiries:
Westwicke Partners
Mike Piccinino, CFA
[email protected]
443-213-0500

 

Press and Media Inquiries:
Organogenesis

[email protected]